231 related articles for article (PubMed ID: 33422061)
1. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
3. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Lin WW; Cheng YA; Li CC; Ho KW; Chen HJ; Chen IU; Huang BC; Liu HJ; Lu YC; Cheng CM; Huang MY; Lai HW; Cheng TL
Sci Rep; 2021 Apr; 11(1):7598. PubMed ID: 33828191
[TBL] [Abstract][Full Text] [Related]
5. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
Kao CH; Wang JY; Chuang KH; Chuang CH; Cheng TC; Hsieh YC; Tseng YL; Chen BM; Roffler SR; Cheng TL
Biomaterials; 2014 Dec; 35(37):9930-9940. PubMed ID: 25212525
[TBL] [Abstract][Full Text] [Related]
6. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
7. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
9. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
10. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity.
Cheng WJ; Lin SY; Chen M; Chen LC; Ho HO; Chuang KH; Sheu MT
Int J Nanomedicine; 2021; 16():4017-4030. PubMed ID: 34140769
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
12. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.
Cheng YA; Wu TH; Wang YM; Cheng TL; Chen IJ; Lu YC; Chuang KH; Wang CK; Chen CY; Lin RA; Chen HJ; Liao TY; Liu ES; Chen FM
J Nanobiotechnology; 2020 Aug; 18(1):118. PubMed ID: 32854720
[TBL] [Abstract][Full Text] [Related]
13. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
15. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
[TBL] [Abstract][Full Text] [Related]
16. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
17. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M
Sci Transl Med; 2023 May; 15(696):eabm1262. PubMed ID: 37196067
[TBL] [Abstract][Full Text] [Related]
18. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
20. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
